Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nezastomig - Regeneron Pharmaceuticals

Next Previous
Drug Profile

Nezastomig - Regeneron Pharmaceuticals

Alternative Names: Anti-PSMAxCD28; Anti-PSMAxCD28 - Regeneron Pharmaceuticals; REGN-5678

Latest Information Update: 04 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 25 Apr 2025 Adverse events and efficacy data from a phase I/II trial in Prostate cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 10 Feb 2025 M.D. Anderson Cancer Center plans a phase I trial for Prostate Cancer (Combination therapy, Metastatic disease, Hormone refractory, Second-line therapy or greater) in USA (IV, Infusion) in May 2025 (NCT06826768)
  • 10 Oct 2023 M.D. Anderson Cancer Center plans a phase I/II trial for Prostate cancer (Late-stage disease, Inoperable/Unresectable) in USA (IV) in March 2024 (NCT06085664)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top